Comment from Mark Walters

Summary: Dr. Mark C. Walters, representing UCSF School of Medicine, supports the proposed Expedited Investigational New Drug Pilot Program while advocating for specific modifications to accommodate cell and gene therapies. He recommends establishing a dedicated CGT-specific QRI track, implementing "firewalling" for dual-capacity institutions, and ensuring that success metrics prioritize safety and manufacturing quality over mere speed.